Drugs / Pro-netupitant
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02517021 | Nov 2015 → Aug 2016 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pro-netupitant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02517021 ↗ |
| Route | Intravenous | “Intravenous Pro-netupitant/Palonosetron (260 mg/0.25 mg) powder for solution for infusion” NCT02517021 ↗ |